RxDoctor Payments DataLook up a doctor →

Janja Viltuznik, MD

Adult Medicine · Orange, CANPI 1639182702

Payments from drug & device makers

$12,663in general payments, 2019–2025

Across 562 payments — averaging $22.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • AbbVie$2K
  • Lilly USA, LLC$1K
  • Pfizer$1K
  • Boehringer Ingelheim$734
  • Johnson & Johnson$632
  • plus $4K from 33 others

What the payments were for

  • Food & beverage$12,53099%
  • Education$1321%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,663 in reported general payments places this provider in the 90th percentile of 221 adult medicine providers in California.

See all adult medicine providers in California

Medicare billing

Part B allowed, 2024
$23,606
Medicare patients
94
Services billed
212

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide44$44,771
JardianceEmpagliflozin47$41,299
OzempicSemaglutide41$39,561
JanuviaSitagliptin Phosphate30$24,014
FarxigaDapagliflozin Propanediol41$23,092
EliquisApixaban19$18,955
GemtesaVibegron16$15,561
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$15,182
MyrbetriqMirabegron23$13,457
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$10,277
SynthroidLevothyroxine Sodium55$6,869
Valsartan151$4,137
Levothyroxine Sodium255$3,261
Atorvastatin Calcium250$2,669
Rosuvastatin Calcium107$2,095

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$1,351$44,77144 claims
Boehringer IngelheimJardiance$734$41,29947 claims
Novo NordiskOzempic$324$39,56141 claims
AstraZenecaFarxiga, Breztri Aerosphere$2,617$33,36959 claims
MerckJanuvia$533$24,01430 claims
PfizerEliquis$1,202$18,95519 claims
Sumitomo Pharma America, Inc.Gemtesa$175$15,56116 claims
GSKTrelegy Ellipta$478$15,18224 claims
Astellas Pharma US IncMyrbetriq$462$13,45723 claims
AbbVieSynthroid$1,699$6,86955 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 221 adult medicine providers in California.

Other adult medicine in Orange

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →